



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 023 903 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
02.08.2000 Bulletin 2000/31

(51) Int. Cl.<sup>7</sup>: A61K 39/02, A61K 39/05,  
A61K 39/09, A61K 39/102,  
A61K 39/104, A61K 39/10,  
A61P 31/04

(21) Application number: 00200216.0

(22) Date of filing: 20.01.2000

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 26.01.1999 EP 99200202

(71) Applicant: Akzo Nobel N.V.  
6824 BM Arnhem (NL)

(72) Inventors:

- Jacobs, Antonius Arnoldus Christiaan  
5995 PS Kessel (NL)
- Goovaerts, Danny  
2460 Lichtaart (BE)

(74) Representative:

Mestrom, Joannes Jozef Louis et al  
N.V. Organon,  
Postbus 20  
5340 BH Oss (NL)

(54) Use of live attenuated bacteria for the manufacture of a submucosal vaccine

(57) The present invention relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.

EP 1 023 903 A1

**Description**

**[0001]** The present invention relates to the use of bacteria for the manufacture of vaccines. Vaccination has been proven through the years to be a very efficient method for the prevention of diseases caused by many different bacteria. Vaccines have the advantage, contrary to e.g. antibiotic or pharmacological therapies, that they are preventing disease rather than curing it. In many fields, e.g. the field of animal husbandry, vaccination is a standard routine. Usually, all animals in a group are vaccinated as a precautionary measure, in order to prevent disease, whereas in practice often only a few animals would have become infected if no vaccine had been given. This explains why for most commonly used vaccines adverse local reactions due to vaccination are not acceptable: it is not acceptable to cause (severe) physical stress in many animals to prevent a (mild) disease in few.

**[0002]** Nevertheless, for most vaccines, especially for the live vaccines that are in most cases preferable to inactivated vaccines, there is a delicate balance between a sufficiently strong triggering of the immune system on the one hand and acceptable local reactions at the site of administration of the vaccine on the other hand. As a rule of thumb, the best live vaccine gives the most severe local reactions, and therefore local reactions are often unavoidable if efficacious protection is needed.

**[0003]** It is an object of the present invention to provide ways to diminish the problem of local reactions of live vaccines without further attenuating the live vaccines.

**[0004]** It was surprisingly found now that when live attenuated bacteria are used for the preparation of a vaccine for administration to submucosal tissue, the thus obtained vaccine when applied submucosally gives good protection and minor local reactions.

**[0005]** This invention is widely applicable in the field of manufacture of systemic vaccines. It is not restricted to any specific bacterium or a specific disease. Practically all live attenuated bacteria that are suitable for the manufacture of a live attenuated vaccine for systemic application are equally suitable for use in this specific invention. Systemic application comprises all applications in which the vaccine is not applied to the mucosa (mucosal application comprises i.a. oral and intranasal vaccination). Systemic application routes comprise i. a. intramuscular application (IM), subcutaneous application (SC), intradermal vaccination (ID), intravenous vaccination (IV) and intraperitoneal vaccination (IP). Of these routes, intramuscular vaccination is in many cases the preferred application route. This is due to the fact that the vaccine, possibly mixed with an adjuvant, is only slowly released from the site of injection. Thus, the immune system is continuously triggered for a relatively long time with an immunogenic dose of the vaccine. This way of administration ensures an adequate

immune response. The disadvantage however is, that many bacterial IM administered vaccines cause large abscesses at the site of injection. These abscesses may stay there from days to months. In those cases in

5 which a live attenuated bacterium must behave relatively virulent in order to trigger an adequate immune response, the bacterium often replicates at the injection site to such a level that the abscess even bursts. Large intramuscular or skin-abscesses are clearly an unacceptable side-effect of vaccination with bacterial live attenuated strains, but unavoidable if further attenuation spoils the immunogenic potential of the bacterium. This causes the dilemma mentioned above, for which the invention offers a solution.

**[0006]** It is certainly unexpected that such soft and vulnerable tissue as submucosal tissue allows the administration of (sometimes even hardly) attenuated live bacterial vaccines:

20 a) without giving the unacceptable abscesses seen with intradermal or intramuscular application, while  
b) at the same time allowing a sufficient immune response to be build up.

25 This is even more unexpected if the level of damage is considered, that many relatively virulent attenuated bacteria cause to their host when given ID or IM. Intradermal or intramuscular vaccination with such bacteria often causes, next to the formation of abscesses, severe lesions at the injection site. The tissue around the injection site often completely disintegrates, leaving large scars. All these disadvantages are hardly or not seen with the uses according to the invention.

**[0007]** Therefore this embodiment of the invention 35 relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration. Mucosal tissue is found i.a. in the mouth, the nose, the lining of the gut, the eye, the vulva and the lips.

**[0008]** Submucosal application is understood to be 40 administration through the upper layer of the mucosa, and into the submucosa. The submucosa is a well-defined layer, known as such in the art. In principle, there is no limit to depth at which vaccination takes place (i.e. the depth of the tip of the needle), with of course the proviso that vaccination takes place in the submucosa. In practice however, the vaccine would not likely be applied deeper than about 5 millimetres from the surface of the mucosa. Generally spoken, smaller distances between the mucosa and the injection site give smaller local effects. A very suitable depth would be in the submucosa between two and four millimetres below the mucosa.

**[0009]** Another attractive way of application is by 55 using a so-called needle-less injector. The use of these injectors is known from intradermal applications, but these injectors are equally suitable for submucosal applications. Due to the softness of mucosal tissue the vaccine, when applied through a needle-less injector,

goes straight through the mucosa and will come to a halt in the submucosal tissue. The depth of the vaccination only depends on the power applied during administration.

[0010] In principle, all submucosal tissue is suitable for submucosal application. In practice however, the submucosal tissue of the lips and, in female animals, the vulva are very practical sites of administration. Especially in horses, dogs and cattle the submucosal tissue of the lips would be the preferable site of administration.

[0011] Therefore, in a preferred form, the live attenuated bacteria are used for the manufacture of a vaccine for administration in the submucosa of the labiae.

[0012] As mentioned above, practically all live attenuated bacteria that are suitable for the manufacture of a live attenuated vaccine for systemic application are suitable for use in this specific invention. There are many important pathogenic bacteria for which the use according to the invention means a great improvement in safety, where the severity of local reactions is concerned. Below, a list of bacteria is presented, all known to cause abscess formation and thus severe tissue damage and skin lesions, when administered intramuscularly. And for all these bacteria there is a reciprocal relation between the decreased immunogenic potential after attenuation on the one hand, and the acceptability of local reactions at the site of administration on the other hand. The invention applies e.g. to the use of live attenuated bacteria that are attenuated forms of horse pathogenic bacteria.

[0013] The following bacteria are examples of the large family of well-established horse pathogenic bacteria:

*Streptococcus equi*, the cause of "Strangles". This disease causes abscesses of lymph nodes of head and neck and systemic infections. The swelling of the lymph nodes causes the horses to be suffocated. No reliable vaccine without adverse local reactions is known so far. *Streptococcus zooepidemicus*, causing respiratory tract infections and pneumonia, opportunistic infections and abortion in horses. *Rhodococcus equi*, causing bronchopneumonia with abscesses and intestinal abscesses. *Corynebacterium pseudotuberculosis*, causing pectoral abscesses and ulcerative lymphangitis. *Pseudomonas mallei*, causing: "Glanders", a disease characterised by pyogranulomatous inflammations, nodular lesions in lung and ulcerative and nodular lesions in skin and respiratory mucosa. *Actinobacillus equili*, a well-known cause of neonatal death, abortion in mares, stillbirth and foal septicaemia and finally *Pasteurella multocida*, causing respiratory tract infections in horses

Horses have in many cases both a high emotional and

economical value to their owners. Especially in the field of thoroughbreds, it would be unacceptable to have horses suffering from abscesses after vaccination.

[0014] Therefore, in a more preferred form of the invention the use relates to a use where the live attenuated bacterium is an attenuated form of a horse pathogenic bacterium.

[0015] In an even more preferred form, the live attenuated bacterium is selected from the group of bacteria comprising *Streptococcus equi*, *Streptococcus zooepidemicus*, *Rhodococcus equi*, *Corynebacterium pseudotuberculosis*, *Pseudomonas mallei*, *Actinobacillus equili* and *Pasteurella multocida*.

[0016] In a still even more preferred form, the live attenuated bacterium is of the species *Streptococcus equi* and/or *Streptococcus zooepidemicus*.

[0017] The invention is equally applicable to a live attenuated bacterium that is an attenuated form of a bacterium that is pathogenic for cattle. The following list gives a number of examples of frequently encountered pathogens in cattle:

25 *Actinomyces pyogenes*, *Staphylococcus aureus*, *Streptococcus agalactiae* and *Streptococcus uberis*, *Nocardia asteroides*, *Corynebacterium bovis*, *Mycoplasma bovis*, and *Mycobacterium bovis*, all well-established causes of bovine mastitis, *Escherichia coli*, causing both bovine mastitis and diarrhoea, *Pasteurella haemolytica* and *P. multocida*, both causing pneumonia and septicaemia, *Brucella abortus*, causing abortion, *Salmonella dublin* and *S. typhimurium*, causing diarrhoea, pneumonia and systemic infections and finally *Leptospira hardjo* as a cause of urinary tract infections.

35 [0018] The invention also applies to a live attenuated bacterium that is an attenuated form of a bacterium that is pathogenic for pigs.

40 [0019] The following list gives a few examples of pig-pathogenic bacteria:

45 *Streptococcus suis* causing polyserositis, *Staphylococcus aureus* causing exudative epidermitis, *Actinobacillus pleuropneumoniae* causing pleuropneumonia, *Pasteurella multocida* causing atrophic rhinitis and pneumonia, *Bordetella bronchiseptica* also causing atrophic rhinitis and pneumonia, *Escherichia coli* causing diarrhoea and edema disease, *Clostridium perfringens* as a cause of diarrhoea and septicaemia, *Salmonella cholerasuis* also a known cause of diarrhoea, *Haemophilus parasuis* also known as the cause of "Glassers disease", *Erysipelothrix rhusiopathiae* causing a disease known as "Erysipelas", *Mycoplasma hyopneumoniae* causing pneumonia, *Serpulina hyoilectariae* as a cause of diarrhoea and *Leptospira pomona* that gives abortion.

[0020] Also, the invention applies to a live attenuated bacterium that is an attenuated form of a bacterium that is pathogenic for dogs.

[0021] Examples of such bacteria are *inter alia* the following bacterial dog pathogens:

*Staphylococcus aureus*, *pyoderma*, *Streptococcus pneumoniae*, *septicaemia* *Bordetella bronchiseptica*, *tracheobronchitis*, *Escherichia coli*, *diarrhoea* *Leptospira canicola* and *icterohaemorrhagiae*, *general* and *urinary tract infections*.

[0022] The manufactured vaccines comprise at least an immunogenically effective amount of a live attenuated bacterium. Immunogenically effective means that the amount of live attenuated bacterium administered at vaccination is sufficient to induce in the host an effective immune response to virulent forms of the bacterium.

[0023] The useful dosage to be administered will vary depending of age, weight and mammal to be vaccinated and the type of pathogen against which vaccination is sought. The vaccine may comprise any dose of bacteria sufficient to evoke an immune response. Doses ranging between  $10^3$  and  $10^{10}$  bacteria are e.g. very suitable doses.

[0024] In addition to an immunogenically effective amount of the live attenuated bacterium described above, the manufactured vaccine also contains a pharmaceutically acceptable carrier. Such a carrier may be as simple as water, but it may e.g. also comprise culture fluid in which the bacteria were cultured. Another suitable carrier is e.g. a solution of physiological salt concentration. Other examples of pharmaceutically acceptable carriers or diluents useful in the present invention include stabilisers such as SPGA, carbohydrates (e.g. sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein containing agents such as bovine serum or skimmed milk and buffers (e.g. phosphate buffer).

[0025] Optionally, one or more compounds having adjuvant activity may be added to the vaccine. Adjuvants are non-specific stimulators of the immune system. They enhance the immune response of the host to the invading pathogen. Examples of adjuvants known in the art are Freunds Complete and Incomplete adjuvants, vitamin E, non-ionic block polymers, muramyl-dipeptides, ISCOMs (immune stimulating complexes, cf. for instance European Patent EP 109942), Saponins, mineral oil, vegetable oil, and Carbopol (a homopolymer). Other suitable adjuvants are for example aluminium hydroxide, phosphate or oxide, oil-emulsions (e.g. of Bayol F (R) or Marcol 52 (R)), saponins or vitamin-E solubilisate.

## EXAMPLES

### Example 1:

5 **Comparison of safety of intramuscular and submucosal administration of two different attenuated *Streptococcus equi* strains.**

[0026] In this experiment the safety and efficacy of 10 live *S. equi* strain TW 928 deletion mutant vaccine and of strain TW 928/sls double mutant vaccine in Diluvac Forte® (obtainable through Intervet Int. B.V., P.O.Box 31, 5830 AA Boxmeer, The Netherlands), both administered submucosally in the lip, were tested. A comparison 15 with the safety of a similar intramuscular vaccination has been made.

[0027] After a 2 weeks acclimatisation period, 20 5 horses were vaccinated submucosally in the lip with strain TW 928 deletion mutant. Vaccination was done at 2 spots in the upper lip and 2 spots lower lip. A needle was used that was provided with a disc of about 1 centimetre diameter, attached at right angles to the needle, and located at about 2.5 millimetres from the tip of the needle. This prevented the tip of the needle to enter the 25 submucosa for more than about 2 millimetre.

[0028] A volume of 200µl of the vaccine, comprising  $10^{8.8}$  bacteria was given at each spot.

[0029] Three other horses were vaccinated subcutaneously in the same way, but with a double mutant: 30 strain TW 928/sls comprising  $10^{8.2}$  bacteria in Diluvac Forte.

[0030] Three horses were vaccinated IM in the neck with comparable doses of the TW 928 deletion mutant strain.

[0031] Two horses were left as controls.

[0032] At 4 weeks after priming vaccination the 40 vaccines were boosted as described above with the same amount of bacteria at similar vaccination sites. At 2 weeks after booster vaccination, all horses were challenged intranasally with  $7.7 \times 10^8$  CFU of the challenge strain *S. equi* strain Arnica in a 2 ml volume. After vaccination the horses were observed for any systemic or local reactions and after challenge, the horses were examined for clinical signs of strangles or any other 45 abnormality.

### Results:

[0033] Horses subjected to intramuscular vaccination 50 in the neck developed large abscesses that reached diameters ranging between 10 and 30 centimetres within weeks after vaccination. These abscesses were persistent and kept growing until they burst.

[0034] Horses subjected to submucosal vaccination 55 appeared in a good condition and had a normal appetite and no significant further systemic reactions were observed.

[0035] After submucosal priming and boosting with

the 928 deletion mutant only small and transient local reactions were found. Most reactions had disappeared at 3 weeks after priming vaccination and at 2 weeks after booster vaccination. The same minor local reactions, but to an even lesser extend, were observed after both vaccinations with the 928/sls double mutant.

[0036] After challenge, the five horses vaccinated submucosally with the TW 928 deletion mutant appeared completely protected. Complete protection was also obtained in the horses vaccinated intramuscularly with the TW 928 deletion mutant.

[0037] Therefore it can be concluded that

- full protection can be obtained with suitable vaccine strains regardless the site of administration; intramuscularly or submucosally.
- hardly any adverse local reactions are found at the site of submucosal administration, whereas intramuscular administration causes large persistent abscesses at the site of administration.

#### Example 2:

##### Comparison of submucosal and intramuscular administration of a strain of the horse pathogenic bacterium *Streptococcus zooepidemicus*.

[0038] In this experiment the safety of submucosal administration of *Strep. z.* was compared to that of intramuscular administration, especially with respect to adverse local reactions.

[0039] Two horses were vaccinated submucosally in the lip with  $7 \times 10^7$  CFU *Strep. z.* in a total volume of 0.2 ml. Two other horses were vaccinated intramuscularly in the neck with the same dose, but in a total volume of 1 ml.

##### Results:

[0040] The intramuscularly vaccinated horses developed large abscesses from the fourth day after vaccination, that grew to an average size, at ten days after vaccination, of about 20 centimetres diameter. These abscesses were persistent.

[0041] The submucosally vaccinated horses only developed minor abscesses with an average size of 2.5 centimetres, beginning at day 5 after vaccination. The abscesses completely disappeared after six days, leaving no traces behind.

#### Example 3:

##### Comparison of submucosal and intramuscular administration of a virulent strain of the bovine pathogenic bacterium *Actinomyces pyogenes*.

[0042] In this experiment the safety of submucosal administration of *A. pyogenes* was compared to that of

intramuscular administration, especially with respect to adverse local reactions.

5 [0043] Two cows were vaccinated submucosally in the vulva with  $1.2 \times 10^{10}$  CFU in a total volume of 0.2 ml. Two other cows were vaccinated intramuscularly in the neck with the same dose, but in a total volume of 1 ml.

##### Results:

10 [0044] In the submucosally vaccinated animals, small abscesses developed after three days, reaching an average size of about 3.5 centimetres diameter. These abscesses decreased in size after a few days.

15 [0045] In the two cows vaccinated intramuscularly in the neck with the same dose, large and more persistent abscesses developed after three days, reaching a diameter of between 9 and 14 centimetres.

##### 20 Claims

1. Use of a live attenuated bacterium for the manufacture of a vaccine for submucosal administration.
- 25 2. Use according to claim 1, characterised in that the vaccine is for administration in the submucosa of the labiae.
3. Use according to claim 1 or 2, characterised in that the live attenuated bacterium is an attenuated form of a horse pathogenic bacterium.
- 30 4. Use according to claim 3, characterised in that the live attenuated bacterium is selected from the group of bacteria comprising *Streptococcus equi*, *Streptococcus zooepidemicus*, *Rhodococcus equi*, *Corynebacterium pseudotuberculosis*, *Pseudomonas mallei*, *Actinobacillus equuli* and *Pasteurella multocida*.
- 35 5. Use according to claim 4, characterised in that the live attenuated bacterium is of the species *Streptococcus equi* and/or *Streptococcus zooepidemicus*.

40

45

50

55



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 00 20 0216

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)						
X	LOHMAN B L ET AL: "Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques." JOURNAL OF MEDICAL PRIMATOLOGY, (1994 FEB-MAY) 23 (2-3) 95-101, XP002108261 Denmark * abstract * * figure 1 * * page 95, right-hand column, line 4 - page 96, left-hand column, line 3 * ---	1,2	A61K39/02 A61K39/05 A61K39/09 A61K39/102 A61K39/104 A61K39/10 A61P31/04						
Y	EP 0 786 518 A (THE PROVOST FELLOWS AND SCHOLARS ... QUEEN ELIZABETH NEAR DUBLIN) 30 July 1997 (1997-07-30) * claims 1-9 * ---	3-5							
A	GB 2 033 223 A (THE SECRETARY OF STATE FOR SOCIAL SERVICES) 21 May 1980 (1980-05-21) * page 1, line 16 * * page 2, line 29 - line 31 * ---	1-5	TECHNICAL FIELDS SEARCHED (Int.Cl.) A61K						
T	EP 0 894 500 A (AKZO NOBEL N.V.) 3 February 1999 (1999-02-03) * claims 1-8 * ---	1-5							
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>19 May 2000</td> <td>Le Flao, K</td> </tr> </table> <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone      Y : particularly relevant if combined with another document of the same category      A : technological background      O : non-written disclosure      P : intermediate document</p> <p>T : theory or principle underlying the invention      E : earlier patent document, but published on, or after the filing date      D : document cited in the application      L : document cited for other reasons      &amp; : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	19 May 2000	Le Flao, K
Place of search	Date of completion of the search	Examiner							
THE HAGUE	19 May 2000	Le Flao, K							

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 20 0216

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-05-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0786518 A	30-07-1997	AU 703942 B AU 1234697 A BR 9700768 A CA 2195935 A CZ 9700214 A JP 9215492 A NZ 314091 A PL 318095 A US 5895654 A	01-04-1999 07-08-1997 03-11-1998 26-07-1997 18-03-1998 19-08-1997 26-06-1998 04-08-1997 20-04-1999
GB 2033223 A	21-05-1980	AU 526799 B AU 5022879 A CA 1130726 A CS 226190 B DE 2963977 D DK 363479 A EP 0009872 A FI 792682 A,B, HU 190893 B HU 181957 B JP 1018056 B JP 1536837 C JP 55069516 A NO 792822 A,B, NZ 191390 A US 4448768 A US 4442085 A ZA 7904413 A	03-02-1983 06-03-1980 31-08-1982 19-03-1984 09-12-1982 02-03-1980 16-04-1980 02-03-1980 28-12-1986 28-11-1983 03-04-1989 21-12-1989 26-05-1980 04-03-1980 25-05-1982 15-05-1984 10-04-1984 27-08-1980
EP 0894500 A	03-02-1999	HU 9801705 A JP 11100329 A	28-05-1999 13-04-1999